Drugs / allogeneic MSCs
allogeneic MSCs
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06103409 | Jun 2021 → Jun 2023 | — | Venezuelan Institute for Scientific Research | Unknown | No outcome recorded |
| Phase 1/2 | NCT06103396 | Jan 2018 → Jan 2022 | disease of bone structure | Venezuelan Institute for Scientific Research | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01448434 | Sep 2011 → Sep 2013 | osteoarthritis, knee | Stempeutics Research Pvt Ltd | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allogeneic MSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01448434 ↗ |
| Known as | Ad-MSC | “The goal of this study is to evaluate the capacity of allogenic mesenchymal stromal cells form bone marrow (BM-MSC) or adipose tissue(Ad-MSC) to induce wound healing in...” NCT06103409 ↗ |
| Known as | BM-MSC | “The goal of this study is to evaluate the capacity of allogenic mesenchymal stromal cells form bone marrow (BM-MSC) or adipose tissue(Ad-MSC) to induce wound healing in...” NCT06103409 ↗1“The goal of this study is to evaluate the bone regeneration capacity of BM-MSC (Bone marrow mesenchymal stromal cells), in patients with nonunion.” NCT06103396 ↗ |
| Known as | MSCs | “Allogeneic MSCs harvested and cultured in osteogenic medium are seeded on collagen scaffold, and mixed with autologous rich plasma clot.” NCT06103396 ↗ |
| Modality | Cell therapy | “BM-MSC (Bone marrow mesenchymal stromal cells)” NCT06103396 ↗ |
| Route | Other | “Single intraarticular dose of allogeneic MSCs” NCT01448434 ↗ |